Comparative Pharmacology
Head-to-head clinical analysis: FINTEPLA versus SPRITAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINTEPLA versus SPRITAM.
FINTEPLA vs SPRITAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.
None Documented
None Documented
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Terminal half-life: 6–8 hours; clinical context: requires twice-daily dosing for stable serum concentrations
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Renal: 66% unchanged; hepatic metabolism: 24% (inactive metabolites); fecal: negligible (<1%)
Category C
Category C
Antiepileptic
Antiepileptic